NexPoint Real Estate Finance, Inc. Q2 FY2026 earnings call

• New Investment Originations

  • The company funded $20.2 million in 14% coupon preferred equity for a multifamily property, $42.6 million in 14% coupon mezzanine debt for a life science property, and an additional $31.9 million against existing commitments in Q2 2026.
  • Over $70 million of the previously announced $190 million+ pipeline of opportunities was closed during the quarter, with a blended return profile that remains well above the company's cost of capital.

• Balance Sheet Improvements

  • The company closed a $375 million drawable term loan facility with Mizuho Capital Markets, used to repay the $180 million 5.75% senior unsecured notes that matured in May 2026. $362.2 million is currently outstanding on the new facility.
  • A concurrent total return swap with Mizuho reduced net interest cost to SOFR + 245 bps, aligning the company's debt structure with its preference for greater balance sheet flexibility and prepayment optionality, while enabling back leverage to enhance returns on new investments.
  • Combined with $22.6 million raised from its Series C preferred offering, management states the company enters the second half of 2026 with one of the cleanest, most flexible capital structures in the commercial mortgage REIT sector. Total debt outstanding is $836.6 million with a weighted average cost of 6.3% and weighted average maturity of 2.6 years.

• Sector Performance Highlights

  • Multifamily/Residential: Blended lease rate growth turned positive 30 bps in July 2026, the first positive reading since early 2025, improving steadily from -1.7% in April 2026. Renewal leases have held up well, with the majority of 2021-2022 vintage rate compression risk not impacting the portfolio as the company did very little lending during that period. National multifamily supply is forecast to decline 49% in 2026 from 2025 and a further 20% in 2027, with new starts running 70% below the 2022 peak. Management expects supply correction to restore residential pricing power.
  • Life Sciences: The company's core Aleife life science asset is 85% leased (up from 71%), anchored by a long-term 245,000 square foot lease to Lila Sciences with expansion options. Demand for purpose-built lab infrastructure has widened materially due to AI, which requires specialized facilities that cannot be met through retrofitting older buildings. Credit quality of the life science portfolio is improving sequentially, with tour activity up 30% from Q1 to Q2 2026, and Q3 2026 tracking ahead of prior periods.
  • Self-Storage: The storage portfolio continues to outperform the broader sector, with occupancy in the low 90% range and rent growth and net operating income materially ahead of sector averages.

NexPoint Real Estate Finance's total investment portfolio held 85 investments with a total outstanding balance of $1.1 billion as of Q2 2026, broken down by sector:

• Life Sciences: 39.4% of total portfolio balance
• Multifamily: 37.6% of total portfolio balance
• Single Family Rental: 15.1% of total portfolio balance
• Storage: 4.2% of total portfolio balance
• Industrial: 2.1% of total portfolio balance
• Marina: 1.6% of total portfolio balance

By investment type, the allocation is:

• Preferred equity investments: 27.8%
• Mezzanine loans: 24.9%
• CMBS B pieces: 17.5%
• Revolving credit facilities: 17.3%
• Senior loans: 6.2%
• IO strips: 4%
• Promissory notes: 2.2%

Reported Q2 2026 financial results: net income of $0.29 per diluted share (vs. $0.54 per diluted share in Q2 2025); earnings available for distribution (EAD) of $0.46 per diluted share (vs. $0.43 per diluted share in Q2 2025); cash available for distribution (CAD) of $0.58 per diluted share (vs. $0.46 per diluted share in Q2 2025). The company paid a $0.50 per share dividend in Q2 2026, covered 1.16x by CAD. Book value per diluted share decreased 1.9% quarter-over-quarter to $18.60.

• Management provided Q3 2026 guidance with a midpoint of $0.43 per diluted share for earnings available for distribution, in a range of $0.38 (low end) to $0.48 (high end).
• Cash available for distribution guidance for Q3 2026 has a midpoint of $0.55 per diluted share, in a range of $0.50 (low end) to $0.60 (high end).
• Reported Q2 2026 earnings came in ahead of the guidance provided in April 2026.

• 2021 and 2022 vintage multifamily loans carry residual lease rate compression risk, though NexPoint had minimal originations during this period so the portfolio has limited exposure.
• Higher interest rates have created refinancing stress for some market participants, which has the potential to create broader credit cracks in the commercial real estate lending sector, even as NexPoint's underwriting standards have limited its exposure to high-risk assets.
• Forward-looking statements carry inherent uncertainty, and actual results may differ from expectations due to factors disclosed in the company's SEC filings, including Form 10-K.

Q: Now that life sciences has grown to nearly 40% of the portfolio (surpassing multifamily for the first time), what is the long-term target allocation between these two sectors, especially given the AI tailwind for life science and improving fundamentals for multifamily? / A: Management states that in a normalized environment, the target allocation for life sciences (including advanced manufacturing/biomanufacturing) is roughly one-third of the portfolio, with residential targeting ~50%. The recent large increase in life sciences exposure came from the unique one-off Alewife opportunity. The Alewife sponsor is currently running a refinancing process, and NexPoint expects to receive a substantial portion of its capital back from this investment, which will mostly be redeployed into residential assets.

Q: CAD has been above the current $0.50 per share dividend for some time, but EAD has been below the dividend for several quarters. When do you expect both EAD and CAD to be sustainably above the dividend, and are you comfortable with the current dividend level? / A: Management confirmed they are comfortable with the current dividend level, as CAD is the gold standard metric the board uses to evaluate distributions. Over time, management expects both EAD and CAD to converge. The recent increase in CAD over the past several quarters has been driven by accretive redeployment of capital from prior preferred equity offerings into new high-return investments.

Q: What is the current underlying credit performance of your multifamily book, across both preferred equity and CMBS B-piece exposure? / A: Management noted that most of the company's multifamily exposure is in agency-quality assets that were already screened by Fannie/Freddie and third-party underwriters before NexPoint invested, so the portfolio has higher average credit quality than peers. NexPoint did very little multifamily lending in 2022-2023, when much of the current market risk originated, and has had no material credit losses or provisions on either B-piece or preferred equity multifamily exposure to date. The company has a team ready to take over and turn around underperforming assets when needed, and management expects new leasing to inflect higher in Q4 2026.

Q: Outside of the high-performing Alewife asset, how is the rest of your life science portfolio performing, given broader sector challenges? / A: Management confirmed that the broader life science portfolio continues to improve sequentially: tour and tenant activity increased 30% quarter-over-quarter in Q2 2026, and Q3 2026 is already tracking ahead of prior periods. Almost all of NexPoint's broader life science exposure originated in 2024-2026 at a distressed reset basis, so the company does not hold the low-yielding 2021-2022 vintage loans that are currently causing credit issues for peer firms.